TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from MIRA Pharmaceuticals, Inc. ( (MIRA) ).
On August 19, 2025, MIRA Pharmaceuticals announced the successful completion of the Single Ascending Dose portion of its Phase 1 trial for oral Ketamir-2, with no safety concerns observed. The company is now progressing to the Multiple Ascending Dose stage and plans to initiate a U.S. Phase 2a trial in the fourth quarter of 2025, following FDA clearance for its Investigational New Drug application.
The most recent analyst rating on (MIRA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.
More about MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing treatments for neuropathic pain. The company is advancing its product, Ketamir-2, through clinical trials to assess its safety and efficacy.
Average Trading Volume: 1,333,577
Technical Sentiment Signal: Strong Buy
For an in-depth examination of MIRA stock, go to TipRanks’ Overview page.